Sintilimab plus chemo-radiation for older adults with advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiotherapy can help people aged 75 or older with locally advanced stomach cancer. It aims to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 75 years or older.
- You have a type of stomach cancer called adenocarcinoma that has spread to nearby lymph nodes but not to distant organs.
- Your cancer is HER2-negative (a specific protein marker).
- You are in generally good health, able to care for yourself, and have normal blood, liver, kidney, and heart function.
- You haven't had prior treatment for advanced stomach cancer, except maybe surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy after surgical removal of stomach cancer can prevent the cancer from returning in older adults (aged 65 and above). The study aims to see if this combination improves outcomes compared to chemotherapy alone.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.